The disclosure provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The disclosure also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des- Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the disclosure to modulate Kallidin or des-Arg10- Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the disclosure. The disclosure further provides methods of making antibodies that specifically bind to des-Argg- Bradykinin and des-Arg10-Kallidin-like peptide.
